Table 2 Summary of feasibility of experimental group and outcome measures for included studies
Author (year) Country | Feasibility of experimental group | Outcome measures | Assessment time | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adherence | Dropout rate | Adverse events | Global Cognition | Memory | Attention | Executive function | Processing speed | Visuospatial Function | Language | Mental health | Quality of life | ||
Aguiñaga (2017) [31] Spain | 85.00% | None | None | MMSE | Logical Memory I and II | DST SDMT | TMT-B Stroop | TMT-A SDMT |  | Word fluency | GDS-15 | QoL-AD, SF-LLFDI | At baseline, 2 months, 4 months, 6 months, and 8 months |
Doi (2017) [34] Japan | 86.00% | 17.91% | None | MMSE | Story memory, Word list memory | Â | TMT-B | TMT-A | Â | Â | Â | Â | At baseline and post-intervention |
Lazarou (2017) [35] Greece | Not reported | 10.81% | Not reported | MoCA MMSE | RBMT1, RBMT2, RAVLT | TEA | Â | Â | ROCFT-copy, ROCFT-delay | FAS | GDS-30 NPI | Â | At baseline and post-intervention |
Dominguez (2018) [33] Philippines | 88.80% | 17.40% | None | MoCA | Â | Â | Â | Â | Â | BNT | GDS-30 NPI | Â | At baseline and post-intervention |
Wu (2019) [36] China | Not reported | 6.90% | None | MoCA MMSE | WMS-RLM | DST SDMT | TMT-B | TMT-A SDMT | Â | Word fluency | GDS-15 | SF-36 | At baseline, 3 months, and 6 months |
Wang (2020) [40] China | 80.29% | 6.06% | None | MoCA MMSE | Â | Â | Â | Â | Â | Â | GDS-15 | SF-12 | At baseline, 1.5 months, and 3 months |
Bisbe (2020) [32] Spain | 95.10% | 5.00% | Not reported | MMSE | WMS-III, RBANS | Â | LVF | TMT-A | JLO | CVF | HADS-depression HADS-anxiety | SF-36 | At baseline and post-intervention |
Zhao (2020) [37] China | Not reported | 12.90% | None | MoCA-P | Â | Â | Â | Â | Â | Â | GDS-30 | Â | At baseline and post-intervention |
Fei (2020) [38] China | Not reported | Not reported | Not reported | MoCA MMSE | Â | Â | TMT-B | TMT-A | Â | Â | Â | Â | At baseline and post-intervention |
Chang (2021) [39] China | Not reported | 13.89% | Not reported | MoCA | Â | Â | Â | Â | Â | Â | GDS-15 | SF-12 | At baseline, 9 weeks, and 18 weeks |